根据web of science粗略计算，纯属娱乐。 journal of medicinal chemistry: 去年5.2,今年看涨，5.3以上。 european journal of medicinal chemistry：去年3.19,今年估计基本不变。 bioorganic medicinal chemistry：一如既往的悲剧，去年2.98,今年很有可能继续下跌，突破3分肯定无望。 organic biomolecular chemistry：去年3.45,今年很有可能突破3.5,甚至3.6。
Medicinal chemistry education: what is needed and where is it going?（药物化学教育:什么是必要的,而它又会用于何处?），这是Povl Krogsgaard-Larsen、Roberto Pelliciari、Noel De Souza、Henk Timmerman、David J. Triggle、C. A. A. van Boeckel和Jan Wasley在2005年《Drug Development Research》第66卷, 第1期, 第1–8页发表的一篇文章的题目。2005年，荷兰诺德维克豪特举行的一次国际教育研讨会上，药物化学教育未来在药物发现过程中的作用被讨论。会议上提出的问题包括：什么是药物化学家必要的知识基础？如何实现和在哪里实现？大学的作用是什么？发展中国家和全球化的影响，药物化学是单一学科吗？有机化学仍然是药物化学这一学科的中心，但现在越来越多的利用构效关系已经成为重要组成部分。此外随着化学生物学的崛起，化学和生物学之间的联系变得更加更重要。行业与大学之间的联系近年来已经显得越来越重要(产学研)，免得有人提醒可能是合适的大学的传统角色不容忽视。会议还指出，西方世界占主导地位的科学在过去的两个世纪已经确保他们一直是药物化学最强的国家，这种优势在今后的数十年间可能会慢慢减少（忧患意识）。 在荷兰诺德维克豪特召开的这届国际教育研讨会上，就药物化学教育（Medicinal chemistry education）达成基本共识：以有机化学为中心的药物化学教育，已经越来越多地融合了化学生物学、系统生物学、结构生物学、生物信息学等学科的内容。除了必需的基础课以外, 大学还须提供合理的课程体系才能达到药物化学教育目的。这代表着国际药物化学教育的最新理念。
今天，偶然翻阅到2000年35卷第1期发表在《European Journal of Medicinal Chemistry（欧洲药物化学杂志）》上的一篇文章，题目是药物化学家的大学教育：八个国家的比较（University education of medicinal chemists: comparison of eight countries）。作者是C.Robin Ganellin、Lester A Mitscher、Bernd Clement、Toshi-Hiko Kobayashi、Emilio Kyburz、 Olivier Lafont、Annie Marcincal、Antonio Monge、Giorgio Tarzia、John G Topliss。文章比较了法国、德国、意大利、日本、西班牙、瑞典、英国和美国等八个国家的药物化学家的大学教育。文章内容还涉及了为攻读药物化学博士学位的学生开设的课程，包括：生物试验、生物化学、组合化学、计算机辅助药物设计、分子模建、定量构效关系、药物分析、药物代谢、酶学、普通实验室技术、分子生物学、NMR分析、有机合成、特殊试剂、专利法规、药物代谢动力学、药理学、物理有机化学、前体药物、放射化学、分离技术、波谱方法、统计学、毒理学。从上面开设的课程数量来看，国外药物化学博士课程的开设时间不会少于1年。所以说药物化学博士攻读四年还是有它的合理性。在作者名单我还看到了John G Topliss的大名，他是“Topliss合成树”的创建者，也是首批使用定量构效关系的科学家之一。 Topliss was part of scientific and man- agement teams that successfully brought a number of drugs to the world market. But one of his most lasting contributions was the development of a more rational, theoretically based approach to analog synthesis than was formerly practiced in the industry. He was one of the first to use quantitative structure-activity relationships (QSARs) methodology, which led him to formulate Operational Schemes for Analog Synthesis in Drug Design (later known as the Topliss Tree) published in 1972, and also the related Manual Hansch Approach, published in 1977. Both are simplified non-mathematical paradigms for rapidly optimizing benzene ring substitution for potency enhancement in a compound series, based on physicochemical principles. The methodology was widely adopted, and is still in use.
药物化学（ medicinal chemistry ）是一门建立在多种化学和生物学科基础上，应用化学和生物学原理研究药物和发展新药的一门交叉学科。国际纯粹化学与应用化学联合会（IUPAC）给出药物化学（ medicinal chemistry ） 的定义是：Medicinal chemistry is a chemistry-based discipline, also involving aspects of biological, medical and pharmaceutical sciences. It is concerned with the invention, discovery, design, identification and preparation of biologically active compounds, the study of their metabolism, the interpretation of their mode of action at the molecular level and the construction of structure-activity relationships（译文：药物化学是一门基于化学的学科，包括生物学、医学、药学科学等。它涉及生物活性物质的发明、发现、设计、鉴定和制备、代谢研究、分子水平上的作用模式及其构效关系）。但是，对于多肽、类脂和糖轭合体在生物医药领域中的应用基础研究似乎应该需要药物化学领域建立一个新的亚学科 - 生物药物化学（ biomedicinal chemistry ） 。 生物大分子在生命过程中扮演着不可替代的作用。历史上，核酸和蛋白质以及多肽的人工合成取得了巨大的成功。随着化学生物学(chemical biology)的出现和发展，近年来，生物大分子的研究呈现出一些新的特点：具有生物特定功能的小RNA的合成与修饰；蛋白质和多肽的合成与修饰，生物活性寡糖的合成与修饰。所以，具有特定生物功能的修饰蛋白或多肽的设计、合成及性质研究、具有重要生物活性的寡糖及其轭合体的合成及功能研究；具有特定生物功能和效应的为导向的寡核苷酸的设计、修饰和研究，逐渐成为相关研究的焦点。 生物药物化学（ biomedicinal chemistry ）主要通过进行学科交叉，集中在应用化学和生物技术上对多肽、脂质及糖轭合体开展研究。从疾病早期发现、生物标志物发现、治疗例如与淀粉样变性蛋白质转体基因疾病、疼痛、脂类代谢障碍、癌症、神经性退行性疾病、自身免疫性疾病、感染性疾病有关的严重人类疾病也是重点。学科研究内容似应包括 基于特定的细胞信号转导途径， 设计合理的多肽、脂质及糖轭合体并研究它们的 ADME/T途径、配体 - 蛋白质相互作用的机制等，以及化学调制的概念，并利用现代药物化学技术利用蛋白质化学、有机化学、分子克隆、分析技术、分子建模、计算化学、 组合化学、高通量筛选、固相有机合成、药物传递系统进行优化 。 生物药物化学（ biomedicinal chemistry ）应当借鉴化学生物学研究的方法和技术成果，研究 大多数多肽、脂质及糖轭合体分子与体内生物大分子 ( 受体、酶、 DNA) 相互作用的目标和行为。随着基于生物技术的方法和工具的发展，使得在类药性的基础上设计能够 与生物 大分子相互作用的靶向分子。
内容简介 Now in its seventh edition, Burger's Medicinal Chemistry, Drug Discovery and Development provides an established, recognized, authoritative and comprehensive source on medicinal chemistry and drug discovery and development. This flagship reference for medicinal chemists and pharmaceutical professions has been thoroughly updated and expanded across 8 volumes to incorporate the entire process of drug development (preclinical testing, clinical trials, etc.) alongside the traditional strengths in medicinal chemistry and drug discovery. 目录 Volume 1: Methods in Drug Discovery(第一卷：药物发现的方法). History of Quantitative Structure Activity Relationships(定量构效关系的历史). Mass spectrometry and drug discovery(质谱法和药物发现). Chirality and Biological Activity(手性和生物活性). Analog design(类似物设计). SNPs: Single Nucleotide Polymorphisms and Pharmacogenomics - individually designed drug therapy(：单核苷酸多态性和药物基因组学-个体设计药物疗法). Design of peptidomimetics(模拟肽物的设计). Dual Acting Drugs(双重作用药物). Combinational chemistry and multiple parallel synthesis(组合化学和多平行合成). Allosteric proteins and drug discovery(别构蛋白和药物发现). Principles of drug metabolism(药物代谢的原理). Pharmacophore-based drug design(基于药效团的药物设计). Use of biological fingerprints vs Structure/chemotypes to describe molecules(生物指纹对结构/化学表型描述分子的用途). Recent advances in development, validation and exploitation of QSAR models(QSAR模型的发展、验证和利用的最新进展). The Application of recombinant DNA Technology in medicinal chemistry and drug discovery(重组DNA技术在药物化学和药物发现中的应用). Structural genomics, its application in Chemistry, Biology, Medicine, and Drug Discovery(结构基因组学在化学、生物学、医学和药物发现中的应用). Volume 2: Discovering Lead Molecules(第二卷：发现先导物分子). Virtual screening(虚拟筛选). Utility and applications of in vitro ADMET profiling in lead discovery(体外ADMET流程先导物发现的用途和应用). Retrometabolism-Based Drug Design and Targeting(基于后代谢的药物设计和靶向). Natural product screening(天然产物筛选). Microbes to man; from the depths to drugs(人体探针：从深处到药物). Multi-objective Optimization For Drug Discovery(药物发现的多目的优化). GPCR homology model development and applications(GPCR同源物建模发展和应用). Structural Alerts for Toxicity(毒性的结构变化). Protein - Protein Interactions as Drug Discovery Targets(作为药物发现靶标的蛋白质-蛋白质相互作用). NMR-based Screening and Drug Discovery(基于NMR筛选和药物发现). Membrane transport proteins and drug transport(膜转运蛋白和药物转运). Receptor targets in drug discovery and development(药物发现和发展中的受体靶标). Selective Toxicities(选择性毒性). Chemogenomics - Systematization of Drug Discovery(化学基因组学-药物发现的系统化). Docking and Scoring in Drug Discovery(药物发现的对接和评分). Recent Trends in Structure-Based Drug Design and Energetics(基于结构药物设计和动力学的最新趋势). QM and QM/MM Approaches to Evaluating Binding Affinities(评价结合力的QM和QM/MM 方法). Assessing the Bioavailability of Drug Delivery Systems: Mathematical Modeling(药物传递系统的生物利用度推测：数学模型). Protein flexibility in in silico screening(虚拟筛选 的蛋白折叠). Volume 3: Drug Development(第三卷：药物发现). Large scale and scale up synthesis(大规模和规模化合成). Physicochemical characterization and principles of oral dosage form selection(理化性质和口服剂型选择原理). The FDA and drug regulatory issues(FDA和药物管理问题). Intellectual property in drug discovery and biotechnology(药物发现和生物技术的知识产权). Polymorphism and conjugation in drug delivery (药物发现的多晶型和识别，结晶动力学(crystal engineering). Prodrugs: Strategic Deployment, Metabolic Considerations and Chemical Design Principles.(前药：策略发展、代谢因素和化学设计原理) Process Development of Protein Therapeutics(蛋白治疗药物的过程发展). Cost-Effectiveness Analyses throughout the Drug Development Life Cycle(药物发现生命周期的效费比分析). Provisional BCS Classification of the Leading Oral Drugs on the Global Market(引领全球市场口服药物BCS临时分类). The role of permeability in drug ADME/PK, interactions and toxicity, and the Permeability-based Classification System (药物ADME/PK的渗透率作用、相互作用和毒性、以及基于渗透率的分类系统，PCS). Salt screening and selection(成盐筛选和选择). Enzymatic assays for HTS or Assay Development for HTS(HTS的酶促试验或发展用于HTS的试验). Crystallographic Survey of the Endogenous Albumin Drug Transport System and its Application in Cancer Chemotherapy(内源性白蛋白药物转运系统的晶体学鉴定及其在癌症化疗中的应用). Nanotechnology in pharmaceuticals(药剂的纳米技术). Volume 4: Cardiovascular, Endocrine and Metabolic Diseases(第四卷：心血管、内分泌和代谢疾病). Diabetes Drugs and Emerging Targets(糖尿病药物和新兴的靶标). DPP-4 inhibitors(DPP-4抑制剂). Nuclear hormone receptor medicinal chemistry(核激素受体药物化学). Thyroid hormones and thyromimetics(甲状腺激素和拟甲状腺激素药物). Antihypertensives:renin inhibitors(抗高血压药物：肾素抑制剂). Antihypertensives - Angiotensin-converting enzyme inhibitors(抗高血压药物：血管紧张素转化酶抑制剂). Atherosclerosis I: LDL Cholesterol Lowering(动脉粥样硬化：降低LDL胆固醇药物). Atherosclerosis I: HDL Elevation(动脉粥样硬化：升高HDL药物). Anticoagulants(抗凝血药物). Antiplatelets(抗血小板药物). Congestive Heart Failure(充血性心力衰竭). Endogenous vasoactive peptides.(内源性) Hematopoietic agents(造血功能治疗药物). Oxygen delivery via allosteric effectors of hemoglobin and blood substitutes(血红素和血液替代品的别构效应物的氧传递). Volume 5: Pulmonary, Bone, Immunology, Vitamins and Autocoid Therapeutic Agents(第五卷：呼吸道、骨骼、免疫学、维生素和自体有效物质治疗药物). Fundamentals of steroid chemistry and biochemistry(甾体化学和生物化学基础). Antiinflammatory Glucocorticoids(抗炎糖皮质激素). Male sex hormones, analogs, and antagonists(雄性激素、类似物和拮抗剂). Female Sex Hormones (pick up from the online)(雌性激素). Medicinal chemistry and therapeutic applications of the gaseotransmitters NO, CO and H2S and their prodrugs(气体信使NO、CO和H2S的药物化学和治疗应用). Retinoids(视黄醇类). Multiple sclerosis(多发性硬化症). Ophthalmic agents(眼科药物). Vitamins(维生素). Drug Discovery in Non-Life Threatening Disorders: Erectile Dysfunction, Insomnia and Smoking Cessation(非生命威胁疾病：勃起功能障碍、失眠和戒烟的药物发现). Osteoporosis therapy: mechanistic antiresoptives(骨质疏松症疗法：mechanistic antiresoptives). Osteoporosis therapy: anabolics(骨质疏松症疗法：合成类固醇). Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease(慢性肺阻塞疾病的当前和新兴疗法). Agents acting on prostanoid TX receptors(作用于前列腺素和TX受体的药物). Therapeutic agents acting on RNA(作用于RNA的治疗药物). Immunosuppressive agents for the prevention of transplantation rejection(预防移植物排斥的免疫抑制剂). Volume 6: Cancer(第六卷：癌症). Natural product cytotoxics(天然产物细胞毒剂). Histone Deacetylase Inhibitors: A brief overview of their role and medicinal chemistry(组蛋白脱乙酰酶抑制剂：它们的作用和药物化学的简述). Synthetic DNA-targeted chemotherapeutic agents and related tumor-activated prodrugs(合成DNA靶向化学治疗药和相关肿瘤活性前药). PARP Inhibitors as Anticancer Agents(作为抗肿瘤药物的PARP抑制剂). Proteasome inhibitors(蛋白酶体抑制剂). CNS Cancers(CNS癌症). Kinase inhibitors: Approved Drugs and Clinical Candidates(激酶抑制剂：批准的药物和临床候选药物). Structure-Based Design of Kinase Inhibitors: Molecular Recognition of Protein Multiple Conformations(基于结构的激酶抑制剂设计：). Cancer drug resistance-targets and therapies(肿瘤药物抗性-靶标和疗法). HSP inhibitors(HSP抑制剂). Gene therapy with plasmid DNA(具有质粒DNA的基因疗法). Volume 7: Antiinfectives(第七卷：抗感染药物). The FDA Approved HIV-1 Protease Inhibitors for Treatment of HIV/AIDS(FDA批准的治疗HIV/AIDS的HIV-1蛋白酶抑制剂). HIV integrase(HIV整合酶). CCR5 Antagonists(CCR5拮抗剂). Reverse Transcriptase Inhibitors (逆转录酶抑制剂，RTIs). Anti HCV agents(抗HCV药物). Anti-DNA Virus Agents(抗DNA病毒药物). β-lactam antibiotics-include monobactams, β-lactamase inhibitors(β-内酰胺抗生素-包括单环内酰胺、β-内酰胺酶抑制剂). Tetracyclines, aminoglycoside, macrolide, and miscellaneous antibiotics(四环素、氨基糖苷、大环内酯和其它抗生素). Synthetic antibacterial agents(合成抗菌药). Antiprotozoal/ Antiparasitic Agents(抗原虫/ 抗锥虫药). Antimalarials(抗疟药). Anti-tuberculosis(抗结核药). Volume 8: CNS Disorders(第八卷：CNS疾病). Chemical Perspective on Neurotransmission and Drug Discovery for the Central Nervous System(神经递质和中枢神经系统药物发现的化学观点). Cognition(促智药). Cholinergics/anticholinergics/muscarinics/nicotinics(拟胆碱能药/抗胆碱能药/毒蕈碱/烟碱). CNS stimulants(CNS兴奋药). Anticonvulsants(抗惊厥药). Antipsychotic agents(抗精神失常药). Antidepressants(抗抑郁药). Therapeutic Agents for the Treatment of Migraine(治疗偏头痛的治疗药物). Approaches to Amyloid Therapies for the Treatment of Alzheimers Disease(治疗阿尔兹海默病的淀粉样治疗方法). Non-Amyloid Approaches to Alzheimer's Disease(阿尔兹海默病的非淀粉样方法). Stroke(中风). Therapeutic and Diagnostic Agents for Parkinson's Disease(帕金森病的治疗和诊断药物). Opioid Receptor Ligands(阿片受体配体). PET and SPECT in Drug Development(药物发现中的PET和SPET).
The Sixth Edition of this well-known text has been fully revised and updated to meet the changing curricula of medicinal chemistry courses. Emphasis is on patient-focused pharmaceutical care and on the pharmacist as a therapeutic consultant, rather than a chemist. A new disease state management section explains appropriate therapeutic options for asthma, chronic obstructive pulmonary disease, and men's and women's health problems. Also new to this edition: Clinical Significance boxes, Drug Lists at the beginning of appropriate chapters, and an eight-page color insert with detailed illustrations of drug structures. Case studies from previous editions and answers to this edition's case studies are available online at thePoint. 目录 Historical Perspective of Medicinal Chemistry (药物化学历史展望) Part I: Principles of Drug Discovery (药物发现原理) Chapter 1. Drug Discovery from Natural Products (天然产物的药物发现) Chapter 2. Drug Design and Relationship of Functional Groups to Pharmacologic Activity (药物设计及官能团与药理活性关系) Chapter 3. Molecular Modeling and in Silico (分子建模与计算机模拟) Chapter 4. Receptors and Drug Action (受体和药物作用) Chapter 5. Drug Discovery Through Enzyme Inhibition (通过酶抑制作用的药物发现) Chapter 6. Pharmaceutical Biotechnology-From Nucleic Acids to Personalized Medicine (制药生物技术-从核酸到个体化药物) Chapter 7. Peptide and Protein Drugs (多肽和蛋白质药物) Chapter 8. Antisense Therapeutic Agents (反义治疗药物) Chapter 9. Physicochemical and Biopharmaceutical Properties of Drug Substances and Pharmacokinetics (药物的理化和生物药剂学性质及药代动力学) Chapter 10. Drug Metabolism (药物代谢) Chapter 11. Drug Regulation: An Overview (药物法规概述) Part II: Drug Receptors Affecting Neurotransmission and Enzymes as Catalytic Receptors (影响神经传递和酶作为催化受体的药物) Overview of Drug Receptors: A Perspective (药物受体概述：展望) Chapter 12. Drugs Affecting Cholinergic Neurotransmission (影响胆碱能神经传递的药物) Chapter 13. Adrenergic Receptors and Drugs Affecting Adrenergic Neurotransmission (肾上腺素能受体和影响肾上腺素能神经传递的药物) Chapter 14. Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission (5-羟色胺受体和影响5-羟色胺能神经传递的药物) Chapter 15. Amino Acid Neurotransmitters in the Central Nervous System (中枢神经系统氨基酸神经传递) Chapter 16. Inhibitors of Nerve Conduction: Local Anesthetics (神经传导抑制剂) Chapter 17. Phosphodiesterase Inhibitors (磷酸二酯酶抑制剂) Part III: Pharmacodynamic Agents (药效动力学治疗剂) Section 1: Drugs Affecting Central Nervous System (影响中枢神经系统的药物) Chapter 18. General Anesthetics (全身麻醉药) Chapter 19. Sedative-Hypnotics (镇静催眠药) Chapter 20. Antiseizure Agents (抗癫痫药) Chapter 21. Antidepressants (抗抑郁药) Chapter 22. Psychotherapeutic Drugs: Antipsychotic and Anxiolytic Agents (精神病治疗药：抗精神失常和抗焦虑药) Chapter 23. Hallucinogens, Stimulants and Related Drugs of Abuse (致幻剂、兴奋剂及相关滥用药物) Chapter 24. Opioid Analgesics (阿片类镇痛药) Chapter 25. Drugs Used to Treat Neuromuscular Disorders: Antiparkinsonian and Spasmolytic Agents (治疗神经肌肉疾病的药物：抗帕金森病药物和解痉药) Section 2: Drugs Affecting the Cardiovascular System(影响心血管系统的药物) Chapter 26. Cardiac Agents: Cardiac Glycosides, Antianginal, and Antiarrhythmic Drugs (强心药：强心苷、抗心绞痛药和抗心律失常药) Chapter 27. Diuretics (利尿药) Chapter 28. Angiotensin Converting Enzyme Inhibitors, Antagonists and Calcium Blockers (血管紧张素转化酶抑制剂、拮抗剂和钙阻滞剂) Chapter 29. Central and Peripheral Sympatholytics and Vasodilators (中枢与外周交感神经阻滞剂和血管扩张药) Chapter 30. Antihyperlipoproteinemics and Inhibitors of Cholesterol Biosynthesis (抗高脂蛋白血症药与胆固醇生物合成抑制剂) Chapter 31. Antithrombotics, Thrombolytics, Coagulants, and Plasma Extenders (抗血栓药) Section 3: Drugs Affecting the Hormonal Systems (影响激素系统的药物) Chapter 32. Insulin and Drugs Used for the Treatment of Diabetes (胰岛素和治疗糖尿病的药物) Chapter 33. Adrenocorticoids (肾上腺皮质激素) Chapter 34. Thyroid Function and Thyroid Drugs (甲状腺功能和甲状腺药物) Chapter 35. Calcium Homeostasis (钙内平衡) Section 4: Drugs Affecting the Immune Systems (影响免疫系统的药物) Chapter 36. Nonsteroidal Anti-Inflammatory Drugs (非甾体抗炎药) Chapter 37. Antihistamines and Related Antiallergic and Antiulcer Agents (抗组胺药及相关抗过敏和抗溃疡药) Section 5: Chemotherapeutic Agents (化学治疗药) Chapter 38. Antibiotics and Antimicrobial Agents (抗生素和抗微生物药物) Chapter 39. Antiparasitic Agents (抗寄生虫药物) Chapter 40. Antifungal Agents (抗真菌药) Chapter 41. Antimycobacterial Agents (抗分支杆菌药) Chapter 42. Cancer and Chemotherapy (癌症和化学疗法) Chapter 43. Antiviral Agents and Protease Inhibitors (抗病毒药和蛋白酶抑制剂) Part IV: Disease State Management (疾病状态控制) Chapter 44. Asthma and Chronic Obstructive Pulmonary Disease (哮喘和慢性肺阻塞疾病) Chapter 45. Men' Health (男性健康) Chapter 46. Women's Health (女性健康) Appendix A: pKa Values for Some Drugs and Miscellaneous Organic Acids and Bases Appendix B: pH Values for Tissue Fluids
European Medicinal Chemistry Education and Training was the subject of a round table discussion at the 5th Joint Meeting on Medicinal Chemistry. This report emphasises the importance of such regular periodic forums to focus education and training towards the principal goal of medicinal chemistry (and medicinal chemists), which is to get better drugs, to cure diseases, and/or (at least) to improve the quality of life of patients.
Medicinal Chemistry: Shades of chemical beauty Peter Kirkpatrick AbstractThe concept of drug-likeness — which is based on the observation that physicochemical properties of drugs, such as molecular mass and lipophilicity, tend to fall within a relatively narrow range of the possible values — is widely used to prioritize compounds in early-stage drug discovery. Hopkins and colleagues, writing in Nature Chemistry, now present a novel approach for assessing drug-likeness that could overcome some important limitations of established approaches and might also better reflect the intuitive assessments of experienced medicinal chemists about the attractiveness of candidate compounds.
剽窃有很多种,但是直接copy显然是最笨的。在今天网络发达的今天，这种剽窃如果能发生在国际名期刊就更少见；而这事情就发生了。很奇怪的是如何绕过了审稿人，要知道Elsevier出版社给审稿人赠送了检索系统使用权。 事情是这样的来自印度的作者直接copy了意大利作者发表在一流药物化学杂志JMC的2001的一篇论文，2010年发表在著名的药物化学杂志《欧洲药物化学杂志》。显然躲得初一躲不过初五 ，估计是被读者或者原作者本人举报了，欧洲药物化学杂志主编很生气。这事情对杂志的声誉也是严重的损害。 撤稿理由;This article has been retracted at the request of the Editor-in-Chief. Reason: The aforementioned paper carries numerous instances of directly copied text from a previous paper published in 2001 in Journal of Medicinal Chemistry 44 (2001) 4359e4369: 。。。。 The paper published in 2010 by Sahoo and Behera directly copies substantial quantities (practically the entire paper) of the original published by Settimo et al. The 2010 paper should therefore be removed for reasons of excessive and direct plagiarism. 我之前还报道了一次作者“非故意”报道了已经存在的“新化合物”在新领域的应用，后来在引用本该引用的论文后还是发表的故事。见前博文。 http://blog.sciencenet.cn/home.php?mod=spaceuid=51231do=blogid=363247 剽窃声明
标签: 药物化学
![[转载]药物化学参考书:Burger's Medicinal Chemistry, Drug Discove](http://image.sciencenet.cn/album/201203/03/135131s8te992be22bba2e.jpg.thumb.jpg)
![[转载]药物化学参考书：Foye's Principles of Medicinal Chemistry](http://image.sciencenet.cn/album/201203/03/1348366lzxo1tsjz4ra3za.jpg.thumb.jpg)
